Paradigm Biocapital Advisors
$5.3B 13F equity value
42 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Paradigm Biocapital Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| RVMD | REVOLUTION MEDICINES INC | 6,361,323 | $1.2B | 22.3% |
| NUVL | NUVALENT INC | 5,924,433 | $732M | 13.7% |
| EWTX | EDGEWISE THERAPEUTICS INC | 10,215,455 | $415M | 7.8% |
| GMAB | GENMAB A/S | 13,133,131 | $361M | 6.8% |
| SYRE | SPYRE THERAPEUTICS INC | 3,840,778 | $341M | 6.4% |
| APGE | APOGEE THERAPEUTICS INC | 1,576,385 | $209M | 3.9% |
| ORKA | ORUKA THERAPEUTICS INC | 2,144,526 | $204M | 3.8% |
| TNGX | TANGO THERAPEUTICS INC | 6,357,523 | $199M | 3.7% |
| BLTE | BELITE BIO INC | 1,232,877 | $190M | 3.6% |
| ERAS | ERASCA INC | 9,550,000 | $175M | 3.3% |
Track Paradigm Biocapital Advisors's 13F portfolio: $5.3B in reported holdings, 42 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}